Last reviewed · How we verify
LipoCol Forte capsules
LipoCol Forte reduces cholesterol levels by inhibiting HMG-CoA reductase and enhancing cholesterol clearance through multiple lipid-lowering pathways.
LipoCol Forte reduces cholesterol levels by inhibiting HMG-CoA reductase and enhancing cholesterol clearance through multiple lipid-lowering pathways. Used for Hypercholesterolemia, Dyslipidemia, Cardiovascular disease prevention.
At a glance
| Generic name | LipoCol Forte capsules |
|---|---|
| Sponsor | National Taiwan University Hospital |
| Drug class | Statin combination / Lipid-lowering agent |
| Target | HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
LipoCol Forte is a combination lipid-lowering formulation that typically contains a statin (such as lovastatin or simvastatin) along with other cholesterol-reducing agents. The statin component inhibits HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, thereby reducing LDL cholesterol production. Additional components may work synergistically to enhance HDL cholesterol and reduce triglycerides through complementary mechanisms.
Approved indications
- Hypercholesterolemia
- Dyslipidemia
- Cardiovascular disease prevention
Common side effects
- Myalgia
- Elevated liver enzymes
- Gastrointestinal disturbance
- Headache
Key clinical trials
- Red Yeast Rice for Primary Prevention of Hypercholesterolemia
- The Pharmacokinetic Study of Red Yeast Rice Capsule Compared to Lovastatin Tablet in Healthy Subjects (PHASE4)
- Pharmacokinetic and Drug Interaction Study of Red Yeast Rice Capsules (PHASE4)
- The Effect of LipoCol Forte® Capsules on the Pharmacokinetics of Nifedipine After Administering Single-dose Combination to Healthy Subjects (PHASE4)
- Lovastatin and Its ß-hydroxy Acid From Four 600 mg LipoCol Forte® Capsules Compared to That of One 20 mg Mevacor® Tablet in Healthy Subjects (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LipoCol Forte capsules CI brief — competitive landscape report
- LipoCol Forte capsules updates RSS · CI watch RSS
- National Taiwan University Hospital portfolio CI